Literature DB >> 35422927

Predictive value of CTRP3 for the disease recurrence of atrial fibrillation patients after radiofrequency ablation.

Zhe Wang1, Chao Liang1, Yuanfeng Gao1, Xianchen Meng2, Hongjie Chi1, Mulei Chen1.   

Abstract

OBJECTIVE: To explore the expression of plasma CTRP3 in patients with non-valvular paroxysmal atrial fibrillation after radiofrequency ablation and its predictive value for disease recurrence.
METHODS: In this retrospective study, the patients in the Heart Center of Beijing Chaoyang Hospital from June 2016 to November 2017 were collected. According to the guidelines for diagnosis and treatment of atrial fibrillation 2016, patients diagnosed with paroxysmal atrial fibrillation were selected as the study subjects. All patients with successful radiofrequency ablation of atrial fibrillation were followed up by telephone or outpatient service at 1, 3, 6 and 12 months after radiofrequency ablation, respectively. Recurrence of atrial fibrillation was defined as a duration of rapid atrial arrhythmia ≥30 seconds confirmed by electrocardiogram or 24-hour ambulatory electrocardiogram 3 months after radiofrequency ablation. According to the follow-up results, the patients were divided into a recurrent group and non-recurrent group. The level of CTRP3 was detected by enzyme-linked immunosorbent assay (ELISA).
RESULTS: Analysis of clinical baseline data showed significant differences between the recurrent group and the non-recurrent group in age, systolic blood pressure, diastolic blood pressure, EGFR, thyroid stimulating hormone level, platelet count, high-sensitivity C-reactive protein, NT proBNP, left atrial anterior posterior diameter, left atrial upper and lower diameter and CTRP3 (P < 0.05). The univariate logistic regression showed that older age (or = 1.08, P < 0.001), increased diastolic blood pressure (OR = 1.051, P = 0.002), cardiac dysfunction (OR = 2.594, P = 0.01), high-sensitivity C-reactive protein (OR = 1.134, P = 0.008) and NT proBNP (OR = 1.000, P = 0.005), increased anterior posterior diameter of left atrium (OR = 1.158, P < 0.001), increased upper and lower diameter of left atrium (OR = 1.133, P < 0.001), thrombocytopenia (OR = -0.008, P < 0.027) and CTRP3 (OR = 1.007, P = 0.006) were the risk factors for the recurrence of atrial fibrillation after radiofrequency ablation. Moreover, the multivariate logistic regression analysis demonstrated that CTRP3 (or = 1.032, P = 0.005) was an independent predictor of recurrence.
CONCLUSION: The plasma concentration of CTRP3 increased significantly in patients with recurrent atrial fibrillation after radiofrequency ablation. Moreover, CTRP3 was a predictor of recurrence after radiofrequency ablation in patients with atrial fibrillation. AJTR
Copyright © 2022.

Entities:  

Keywords:  Atrial fibrillation; CTRP3; atrial fibrosis; catheter ablation; recurrence

Year:  2022        PMID: 35422927      PMCID: PMC8991134     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  32 in total

1.  A novel adipokine C1q/TNF-related protein 3 is expressed in developing skeletal muscle and controls myoblast proliferation and differentiation.

Authors:  Masataka Otani; Souhei Furukawa; Satoshi Wakisaka; Takashi Maeda
Journal:  Mol Cell Biochem       Date:  2015-08-14       Impact factor: 3.396

2.  Box Isolation of Fibrotic Areas (BIFA): A Patient-Tailored Substrate Modification Approach for Ablation of Atrial Fibrillation.

Authors:  Hans Kottkamp; Jan Berg; Roderich Bender; Andreas Rieger; Doreen Schreiber
Journal:  J Cardiovasc Electrophysiol       Date:  2015-11-20

3.  Total and interatrial epicardial adipose tissues are independently associated with left atrial remodeling in patients with atrial fibrillation.

Authors:  Seung Yong Shin; Hwan Seok Yong; Hong Euy Lim; Jin Oh Na; Cheol Ung Choi; Jong Il Choi; Seong Hwan Kim; Jin Won Kim; Eung Ju Kim; Sang Weon Park; Seung-Woon Rha; Chang Gyu Park; Hong Seog Seo; Dong Joo Oh; Young-Hoon Kim
Journal:  J Cardiovasc Electrophysiol       Date:  2011-01-15

4.  C1q/tumor necrosis factor-related protein-3, a newly identified adipokine, is a novel antiapoptotic, proangiogenic, and cardioprotective molecule in the ischemic mouse heart.

Authors:  Wei Yi; Yang Sun; Yuexing Yuan; Wayne Bond Lau; Qijun Zheng; Xiaoliang Wang; Yajing Wang; Xiying Shang; Erhe Gao; Walter J Koch; Xin-Liang Ma
Journal:  Circulation       Date:  2012-05-31       Impact factor: 29.690

5.  C1q tumor necrosis factor-related protein-3 protects mesenchymal stem cells against hypoxia- and serum deprivation-induced apoptosis through the phosphoinositide 3-kinase/Akt pathway.

Authors:  Meng Hou; Jingjin Liu; Fang Liu; Kai Liu; Bo Yu
Journal:  Int J Mol Med       Date:  2013-11-07       Impact factor: 4.101

6.  Circulating adiponectin levels in patients with atrial fibrillation.

Authors:  Masayuki Shimano; Rei Shibata; Yukiomi Tsuji; Hiromi Kamiya; Tomohiro Uchikawa; Shuji Harata; Masahiro Muto; Noriyuki Ouchi; Yasuya Inden; Toyoaki Murohara
Journal:  Circ J       Date:  2008-07       Impact factor: 2.993

Review 7.  Origin of myofibroblasts and cellular events triggering fibrosis.

Authors:  Matthias Mack; Motoko Yanagita
Journal:  Kidney Int       Date:  2014-08-27       Impact factor: 10.612

8.  Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes.

Authors:  Anna M Wolf; Dominik Wolf; Holger Rumpold; Barbara Enrich; Herbert Tilg
Journal:  Biochem Biophys Res Commun       Date:  2004-10-15       Impact factor: 3.575

Review 9.  C1q and tumor necrosis factor superfamily: modularity and versatility.

Authors:  Uday Kishore; Christine Gaboriaud; Patrick Waters; Annette K Shrive; Trevor J Greenhough; Kenneth B M Reid; Robert B Sim; Gerard J Arlaud
Journal:  Trends Immunol       Date:  2004-10       Impact factor: 16.687

10.  C1q/TNF-related protein-3 (CTRP-3) and pigment epithelium-derived factor (PEDF) concentrations in patients with type 2 diabetes and metabolic syndrome.

Authors:  Kyung Mook Choi; Soon Young Hwang; Ho Cheol Hong; Sae Jeong Yang; Hae Yoon Choi; Hye Jin Yoo; Kwan Woo Lee; Moon Suk Nam; Yong Soo Park; Jeong Taek Woo; Young Seol Kim; Dong Seop Choi; Byung-Soo Youn; Sei Hyun Baik
Journal:  Diabetes       Date:  2012-07-26       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.